Form 4: Nautilus Biotechnology Director McIlwain Acquires 45,000 Stock Options
SEC Form 4 Filing
Matthew S. McIlwain, a director at Nautilus Biotechnology, acquired 45,000 stock options on June 14, 2024, according to a recent SEC filing.
Summary
- On June 14, 2024, Matthew S. McIlwain, a director of Nautilus Biotechnology, Inc., acquired 45,000 stock options.
- The exercise price of these options is $2.56.
- The options vest monthly over a year, contingent upon McIlwain's continuous service as defined in the company's 2021 Equity Incentive Plan.
- The options expire on June 14, 2034.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could be perceived positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 06/14/2024 | Date of the transaction: Matthew S. McIlwain acquired 45,000 stock options. |
| 06/14/2024 | Date the stock options were granted. |
| 06/17/2024 | Date of signature by Attorney-in-Fact. |
| 06/14/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.